Elucidating a key anti-HIV-1 and cancer-associated Axis: The structure of CCL5 (Rantes) in complex with CCR5

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Tamamis, Phanourios ^a   Floudas, Christodoulos A ^a  

^a Princeton University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; GLYCOPROTEIN GP 120; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; PROTEIN BINDING; RANTES; TUMOR PROTEIN;

ANIMAL; BINDING SITE; CHEMICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; HUMAN; PROTEIN CONFORMATION; ULTRASTRUCTURE;

ANIMALS; BINDING SITES; CHEMOKINE CCL5; COMPUTER SIMULATION; HIV ENVELOPE PROTEIN GP120; HUMANS; MODELS, CHEMICAL; MODELS, MOLECULAR; NEOPLASM PROTEINS; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, CCR5;

EID: 84903289235     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep05447     Document Type: Article

References (64)

1. Weitzenfeld, P. & Ben-Baruch, A. The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer. Cancer Lett. In Press, doi:10.1016/j.canlet.2013.10.006. (2013).
2. Bachelerie, F. et al International Union of Pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol. Rev. 66, 1-79 (2013).
3. Soria, G. & Ben-Baruch, A. [The CCL5/CCR5 Axis in Cancer]. Cancer Drug Discovery and Development: Chemokine Receptors in Cancer. [Fulton, A. (ed.)] [109-130] (Humana Press, New York, 2009).
4. Luther, S. A.& Cyster, J. G. Chemokines as regulators of T cell differentiation. Nat. Immunol. 2, 102-107 (2001). (Pubitemid 33707926)
5. Murphy, P. M. et al International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 52, 145-176 (2000). (Pubitemid 30127598)
6. Tyner, J. W. et al CCL5-CCR5 interaction provides antiapoptotic signals for macrophage survival during viral infection. Nat Med. 11, 1180-1187 (2005). (Pubitemid 43093665)
7. Sullivan, N. L. et al Importance of the CCR5-CCL5 axis for mucosal Trypanosoma cruzi protection and B cell activation. J. Immunol. 187, 1358-1368 (2011).
8. Ishida, Y. et al Pivotal role of the CCL5/CCR5 interaction for recruitment of endothelial progenitor cells in mouse wound healing. J. Clin. Invest. 122, 711-721 (2012).
9. Tamamis, P. & Floudas, C. A. Molecular recognition of CCR5 by an HIV-1 gp120 V3 loop. PLoS ONE 9, e95767 (2014).
10. Tamamis, P. & Floudas, C. A. Molecular recognition of CXCR4 by a dual tropic HIV-1 gp120 V3 loop. Biophys J. 105, 1502-1514 (2013).
11. Nardese, V. et al Structural determinants of CCR5 recognition and HIV-1 blockade in RANTES. Nat Struct Biol. 8, 611-615 (2001). (Pubitemid 32613010)
12. Coffey, M. J., Woffendin, C., Phare, S. M., Strieter, R. M. & Markovitz, D. M. RANTES inhibits HIV-1 replication in human peripheral blood monocytes and alveolar macrophages. Am. J. Physiol. 272, L1025-9 (1997).
13. Lusso, P. et al Molecular engineering of RANTES peptide mimetics with potent anti-HIV-1 activity. FASEB J. 25, 1230-1243 (2011).
14. Choi, W. T. et al CCR5 mutations distinguish N-terminal modifications of RANTES (CCL5) with agonist versus antagonist activity. J. Virol. 86, 10218-10220 (2012).
15. Gaertner, H. et al Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide. Proc. Natl. Acad. Sci. USA. 105, 17706-17711 (2008).
16. Luboshits, G. et al Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res. 59, 4681-4687 (1999). (Pubitemid 29428976)
17. Hartmann, M. C. et al Relationship between CCL5 and transforming growth factor-b1 (TGFb1) in breast cancer. Eur. J. Cancer. 47, 1669-1675 (2011).
18. Niwa, Y. et al Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin. Cancer Res. 7, 285-289 (2001). (Pubitemid 32183031)
19. Cambien, B. et al CCL5 neutralization restricts cancer growth and potentiates the targeting of PDGFRb in colorectal carcinoma. PLoS ONE. 6, e28842 (2011).
20. Vaday, G. G., Peehl, D. M., Kadam, P. A. & Lawrence, D. M. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate. 66, 124-134 (2006). (Pubitemid 43191234)
21. Wang, S. W. et al CCL5 and CCR5 interaction promotes cell motility in human osteosarcoma. PLoS ONE. 7, e35101 (2012).
22. Zhou, N. et alMolecular modeling and site-directed mutagenesis of CCR5 reveal residues critical for chemokine binding and signal transduction. Eur. J. Immunol. 30, 164-173 (2000). (Pubitemid 30011777)
23. Fano, A., Ritchie, D. W. & Carrieri, A. Modeling the structural basis of human CCR5 chemokine receptor function: from homology model building and molecular dynamics validation to agonist and antagonist docking. J. Chem. Inf. Model. 46, 1223-1235 (2006). (Pubitemid 43999166)
24. Pakianathan, D. R., Kuta, E. G., Artis, D. R., Skelton, N. J. & Heert, C. A. Distinct but overlapping epitopes for the interaction of a CC-chemokine with CCR1, CCR3 and CCR5. Biochemistry. 36, 9642-9648 (1997). (Pubitemid 27364674)
25. Proudfoot, A. E. et al Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J. Biol. Chem. 271, 2599-2603 (1996). (Pubitemid 26047869)
26. Govaerts, C. et al The TXP motif in the second transmembrane helix of CCR5. A structural determinant of chemokine-induced activation. J. Biol. Chem. 276, 13217-13225 (2001).
27. Govaerts, C. et al Activation of CCR5 by chemokines involves an aromatic cluster between transmembrane helices 2 and 3. J. Biol. Chem. 278, 1892-1903 (2003). (Pubitemid 36801429)
28. Thiele, S. et al Allosteric and orthosteric sites in CC chemokine receptor (CCR5), a chimeric receptor approach. J. Biol Chem. 286, 37543-37554 (2011).
29. Rabut, G. E., Konner, J. A., Kajumo, F., Moore, J. P. & Dragic, T. Alanine substitutions of polar and nonpolar residues in the amino-terminal domain of CCR5 differently impair entry of macrophage-and dualtropic isolates of human immunodeficiency virus type 1. J. Virol. 72, 3464-3468 (1998). (Pubitemid 28175601)
30. Kondru, R. et al Molecular interactions of CCR5 with major classes of small molecule anti-HIV CCR5 antagonists. Mol. Pharmacol. 73, 789-800 (2008). (Pubitemid 351397884)
31. Blanpain, C. et al The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle. J. Biol. Chem. 278, 5179-5187 (2003). (Pubitemid 36801030)
32. Blanpain, C. et al Multiple charged and aromatic residues in CCR5 aminoterminal domain are involved in high affinity binding of both chemokines and HIV-1 Env protein. J. Biol. Chem. 274, 34719-34727 (1999). (Pubitemid 129509512)
33. Maeda, K. et al Structural and molecular interactions of CCR5 inhibitors with CCR5. J. Biol. Chem. 281, 12688-12698 (2006). (Pubitemid 43855359)
34. Nardese, V. et al Structural determinants of CCR5 recognition and HIV-1 blockade in RANTES. Nat. Struct. Biol. 8, 611-615 (2001). (Pubitemid 32613010)
35. Dragic, T. et al Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry. J. Virol. 72, 279-285 (1998). (Pubitemid 28048838)
36. Martin, L. et al Structural and functional analysis of the RANTESglycosaminoglycans interactions. Biochemistry. 40, 6303-6318 (2001). (Pubitemid 32472719)
37. Schnur, E. et al NMR mapping of RANTES surfaces interacting with CCR5 using linked extracellular domains. FEBS J. 280, 2068-2084 (2013).
38. Chung, C. W., Cooke, R. M., Proudfoot, A. E. & Wells, T. N. The threedimensional solution structure of RANTES. Biochemistry. 34, 9307-9314 (1995).
39. Wang, X., Watson, C., Sharp, J. S., Handel, T. M. & Prestegard, J. H. Oligomeric structure of the chemokine CCL5/RANTES from NMR, MS, and SAXS data. Structure. 19, 1138-1148 (2011).
40. Tan, Q. et al Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science. 341, 1387-1390 (2013).
41. Wu, B. et al Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science. 330, 1066-1071 (2010).
42. Tamamis, P. & Floudas, C. A. Elucidating a Key Component of Cancer Metastasis: CXCL12 (SDF-1a) Binding to CXCR4. J. Chem. Inf. Model. 54, 1174-1188 (2014).
43. Frishman, D. & Argos, P. Knowledge-based protein secondary structure assignment. Proteins. 23, 566-579 (1995). (Pubitemid 26009520)
44. Zhang, Y. & Skolnick, J. TM-align: A protein structure alignment algorithm based on TM-score. Nucleic Acids Res. 33, 2302-2309 (2005). (Pubitemid 41439897)
45. Huang, C. C. et al Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science. 317, 1930-1934 (2007).
46. Loez de Victoria, A., Tamamis, P., Kieslich, C. A. & Morikis, D. Insights into the Structure, Correlated Motions, and Electrostatic Properties of Two HIV-1 gp120 V3 Loops. PLoS ONE. 7, e49925 (2012).
47. Bellows-Peterson, M. L. et al De novo peptide design with C3a receptor agonist and antagonist activities: theoretical predictions and experimental validation. J. Med. Chem. 55, 4159-4168 (2012).
48. Bellows, M. L. et al A Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework. Biophys. J. 99, 3445-3453 (2010).
49. Tamamis, P. et al Molecular dynamics in drug design: new generations of compstatin analogs. Chem. Biol. Drug. Des. 79, 703-718 (2012).
50. Gorham, R. D. Jr. et al Novel compstatin family peptides inhibit complement activation by drusen-like deposits in human retinal pigmented epithelial cell cultures. Exp. Eye. Res. 116, 96-108 (2013).
51. Smadbeck, J., Peterson, M. B., Khoury, G. A., Taylor, M. S. & Floudas, C. A. Protein WISDOM: a workbench for in silico de novo design of biomolecules. J. Vis. Exp. 77, e50476 (2013).
52. Klepeis, J. L. et al Integrated Computational and Experimenal Approach for Lead Optimization and Design of Compstatin Variants with Improved Activity. J. Am. Chem. Soc. 125, 8422-8423 (2003). (Pubitemid 36858397)
53. Klepeis, J. L., Floudas, C. A., Morikis, D. & Lambris, J. D. Design of Peptide Analogs with Improved Activity using a Novel de novo Protein Design Approach. Ind. Eng. Chem. Res. 43, 3817-3826 (2004). (Pubitemid 38859258)
54. Im, W., Feig, M. & Brooks, C. L. III. An implicit membrane generalized born theory for the study of structure, stability and interactions ofmembrane proteins. Biophys. J. 85, 2900-2918 (2003). (Pubitemid 37345782)
55. Brooks, B. R. et al CHARMM: the biomolecular simulation program. J. Comput. Chem. 30, 1545-1614 (2009).
56. Haberthu, U. & Caflisch, A. J. FACTS: Fast analytical continuum treatment of solvation. J. Comput. Chem. 29, 701-715 (2008).
57. Tamamis, P., Kasotakis, E., Mitraki, A. & Archontis, G. Amyloid-like selfassembly of peptide sequences from the adenovirus fiber shaft: insights from molecular dynamics simulations. J. Phys. Chem. B. 113, 15639-15647 (2009).
58. Tamamis, P. & Archontis, G. Amyloid-like self-assembly of a dodecapeptide sequence from the adenovirus fiber shaft: Perspectives from molecular dynamics simulations. J. Non-Cryst. Solids. 357, 717-722 (2011).
59. Tamamis, P. et al Self-assembly of an aspartate-rich sequence from the adenovirus fiber shaft: insights from molecular dynamics simulations and experiments. J. Phys. Chem. B. 118, 1765-1774 (2014).
60. Seeber, M., Cecchini, M., Rao, F., Settanni, G. & Caflisch, A.Wordom: a program for efficient analysis of molecular dynamics simulations. Bioinformatics. 23, 2625-2627 (2007). (Pubitemid 350048368)
61. Im, W., Lee, M. S. & Brooks, C. L. III. Generalized Born Model with a Simple Smoothing Function. J. Comput. Chem. 24, 1691-1702 (2003).
62. Pierce, B. G., Hourai, Y. & Weng, Z. Accelerating protein docking in ZDOCK using an advanced 3D convolution library. PLoS One. 6, e24657 (2011).
63. Tamamis, P., Morikis, D., Floudas, C. A. & Archontis, G. Species specificity of the complement inhibitor compstatin investigated by all-atom molecular dynamics simulations. Proteins. 78, 2655-2667 (2010).
64. Tamamis, P. et al Design of a modified mouse protein with ligand binding properties of its human analog by molecular dynamics simulations: the case of C3 inhibition by compstatin. Proteins. 79, 3166-3179 (2011).